Article
SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.
The Prostate - 1 Jun 2026
Park Joseph J, Tseng Chin-Lin, Giagtzis Alexandros, Kelley Michael J, Bitting Rhonda L
Abstract excerpt
BACKGROUND: Inactivating missense mutations in the tumor suppressor gene speckle-type pox virus and zinc finger protein (SPOP) occur in 5%-15% of men with prostate cancer (PC). SPOP mutations increase androgen receptor-mediated transcription and enhance sensitivity to hormonal therapies. Here we describe the clinical characteristics, outcomes, and mutational patterns in Veterans with SPOP-mutated PC. METHODS:...
Topics
Join the communities discussing this publication.